# Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 14.4 | 97.5 | (53.3-163.6) |  | Male | 12 | 9.9 | 121.0 | (62.5-211.4) |
| Female | 7 | 5.9 | 119.1 | (47.7-245.4) |  | Female | 8 | 8.8 | 91.0 | (39.2-179.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 3.0 | nc | (nc-nc) |  | Male | 7 | 3.2 | 220.2 | (88.2-453.8) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 4 | 8.7 | nc | (nc-nc) |
| Female | 59 | 72.4 | 81.5 | (62.0-105.1) |  | Female | 6 | 8.4 | 71.6 | (26.2-155.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 7.8 | 89.2 | (35.7-183.7) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 8 | 3.9 | 206.9 | (89.1-407.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 15.9 | 138.1 | (86.5-209.1) |  |  |  |  |  |  |
| Female | 20 | 16.7 | 120.0 | (73.3-185.4) |  | Female | 5 | 6.2 | 80.8 | (26.1-188.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 4.0 | 151.7 | (55.4-330.2) |  | Male | 7 | 5.6 | 125.3 | (50.2-258.2) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 3 | 6.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 42 | 48.8 | 86.1 | (62.1-116.4) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 9.4 | 181.2 | (105.5-290.1) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 7 | 5.7 | 123.4 | (49.4-254.3) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 6 | 0.8 | 741.1 | (270.6-1613.1) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.0 | 83.2 | (26.8-194.1) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 6 | 4.9 | 121.7 | (44.4-264.8) |  | Female | 16 | 13.9 | 115.4 | (65.9-187.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 5.7 | 105.4 | (38.5-229.4) |  |  |  |  |  |  |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 18 | 17.2 | 104.7 | (62.0-165.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 35 | 26.5 | 132.3 | (92.2-184.0) |  | Male | 216 | 198.1 | 109.0 | (95.0-124.6) |
| Female | 41 | 32.0 | 128.3 | (92.0-174.0) |  | Female | 245 | 235.5 | 104.0 | (91.4-117.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

10

# Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 21.6 | 87.9 | (52.9-137.3) |  | Male | 17 | 15.1 | 112.3 | (65.4-179.8) |
| Female | 4 | 7.9 | nc | (nc-nc) |  | Female | 16 | 12.4 | 128.9 | (73.6-209.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.7 | 128.4 | (46.9-279.5) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 16 | 13.4 | 119.8 | (68.5-194.6) |
| Female | 118 | 103.5 | 114.1 | (94.4-136.6) |  | Female | 8 | 11.6 | 69.2 | (29.8-136.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 12.2 | 81.8 | (39.2-150.5) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 5 | 5.3 | 94.9 | (30.6-221.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 25.1 | 95.5 | (61.2-142.1) |  |  |  |  |  |  |
| Female | 20 | 24.2 | 82.8 | (50.5-127.8) |  | Female | 8 | 8.6 | 93.0 | (40.0-183.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 6.0 | 100.8 | (36.8-219.4) |  | Male | 7 | 8.5 | 82.6 | (33.1-170.2) |
| Female | 3 | 1.6 | nc | (nc-nc) |  | Female | 8 | 8.2 | 97.2 | (41.9-191.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 79 | 72.3 | 109.3 | (86.5-136.2) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 14.5 | 48.4 | (19.4-99.8) |  | Male | 3 | 5.4 | nc | (nc-nc) |
| Female | 10 | 7.8 | 127.9 | (61.2-235.2) |  | Female | 1 | 3.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 9.2 | 86.7 | (37.4-170.9) |  | Male | 7 | 7.0 | 100.7 | (40.3-207.4) |
| Female | 9 | 6.7 | 134.3 | (61.3-255.0) |  | Female | 20 | 20.3 | 98.5 | (60.1-152.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 8.7 | 68.7 | (25.1-149.6) |  |  |  |  |  |  |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 14 | 22.7 | 61.6 | (33.7-103.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 38.9 | 46.3 | (27.4-73.1) |  | Male | 257 | 299.7 | 85.7 | (75.6-96.9) |
| Female | 27 | 42.2 | 64.0 | (42.2-93.1) |  | Female | 307 | 327.4 | 93.8 | (83.6-104.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

11

# Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 13.4 | 148.8 | (90.9-229.9) |  | Male | 4 | 8.5 | nc | (nc-nc) |
| Female | 4 | 4.3 | nc | (nc-nc) |  | Female | 5 | 5.8 | 86.3 | (27.8-201.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 4 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 9 | 7.4 | 121.0 | (55.2-229.7) |
| Female | 50 | 47.8 | 104.6 | (77.6-137.9) |  | Female | 13 | 5.9 | 221.2 | (117.7-378.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 6.0 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 13.7 | 131.5 | (77.9-207.9) |  |  |  |  |  |  |
| Female | 13 | 12.0 | 108.0 | (57.4-184.7) |  | Female | 5 | 4.1 | 123.3 | (39.7-287.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 4 | 4.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 7 | 4.5 | 155.3 | (62.2-319.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 44 | 36.5 | 120.6 | (87.6-162.0) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 7.3 | 68.4 | (22.1-159.7) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.4 | nc | (nc-nc) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 8 | 3.3 | 240.9 | (103.7-474.7) |  | Female | 8 | 8.3 | 96.0 | (41.3-189.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 6 | 11.0 | 54.5 | (19.9-118.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 30 | 22.8 | 131.3 | (88.6-187.5) |  | Male | 178 | 163.8 | 108.7 | (93.3-125.9) |
| Female | 22 | 23.2 | 95.0 | (59.5-143.9) |  | Female | 165 | 159.9 | 103.2 | (88.0-120.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

12

# Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 9.9 | 70.8 | (28.4-145.9) |  | Male | 5 | 6.1 | 81.6 | (26.3-190.5) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 3 | 5.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 3 | 1.6 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 5.4 | 110.7 | (40.4-240.9) |
| Female | 35 | 41.8 | 83.8 | (58.4-116.6) |  | Female | 7 | 5.1 | 136.2 | (54.6-280.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 4.5 | 112.0 | (36.1-261.4) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 10.0 | 129.8 | (69.1-222.0) |  |  |  |  |  |  |
| Female | 8 | 10.7 | 75.0 | (32.3-147.7) |  | Female | 1 | 3.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 6 | 3.6 | 167.0 | (61.0-363.6) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 7 | 3.9 | 178.9 | (71.7-368.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 22 | 29.6 | 74.3 | (46.6-112.5) |
| Female | 2 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 5.5 | 109.9 | (40.1-239.3) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 3.9 | 154.7 | (56.5-336.6) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 6 | 7.3 | 81.7 | (29.8-177.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 6 | 9.5 | 63.2 | (23.1-137.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 17.1 | 116.7 | (71.3-180.2) |  | Male | 125 | 123.1 | 101.6 | (84.5-121.0) |
| Female | 20 | 20.0 | 100.1 | (61.1-154.7) |  | Female | 118 | 139.8 | 84.4 | (69.9-101.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

13

# Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 34 | 35.2 | 96.7 | (66.9-135.1) |  | Male | 20 | 22.1 | 90.6 | (55.3-140.0) |
| Female | 8 | 13.7 | 58.6 | (25.2-115.4) |  | Female | 15 | 18.0 | 83.5 | (46.7-137.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 6.3 | 78.8 | (25.4-183.8) |  | Male | 10 | 7.1 | 139.9 | (67.0-257.3) |
| Female | 5 | 5.7 | 87.2 | (28.1-203.4) |  | Female | 7 | 6.3 | 111.2 | (44.5-229.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 20 | 19.5 | 102.5 | (62.6-158.4) |
| Female | 141 | 143.2 | 98.4 | (82.9-116.1) |  | Female | 20 | 18.3 | 109.4 | (66.8-169.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 24 | 16.3 | 147.2 | (94.3-219.0) |
| Female | 6 | 4.5 | 132.5 | (48.4-288.4) |  | Female | 12 | 8.0 | 149.6 | (77.2-261.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 38 | 36.1 | 105.2 | (74.5-144.5) |  |  |  |  |  |  |
| Female | 34 | 38.8 | 87.7 | (60.7-122.5) |  | Female | 7 | 12.5 | 56.1 | (22.5-115.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 8.8 | nc | (nc-nc) |  | Male | 8 | 12.9 | 61.9 | (26.6-121.9) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 17 | 14.4 | 118.2 | (68.8-189.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 87 | 106.1 | 82.0 | (65.7-101.2) |
| Female | 2 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 28 | 19.8 | 141.2 | (93.8-204.0) |  | Male | 8 | 8.2 | 97.9 | (42.2-192.9) |
| Female | 11 | 11.6 | 94.7 | (47.2-169.5) |  | Female | 4 | 5.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 5.1 | 136.7 | (54.8-281.7) |  | Male | 1 | 4.0 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 13.8 | 115.7 | (66.1-188.0) |  | Male | 3 | 8.4 | nc | (nc-nc) |
| Female | 7 | 10.7 | 65.3 | (26.1-134.5) |  | Female | 20 | 25.0 | 80.0 | (48.8-123.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 12.3 | 106.1 | (56.4-181.5) |  |  |  |  |  |  |
| Female | 5 | 4.5 | 111.3 | (35.9-259.8) |  | Female | 27 | 32.6 | 82.8 | (54.5-120.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 72 | 61.5 | 117.0 | (91.5-147.3) |  | Male | 432 | 442.0 | 97.7 | (88.7-107.4) |
| Female | 88 | 69.7 | 126.3 | (101.3-155.6) |  | Female | 481 | 490.0 | 98.2 | (89.6-107.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

14

# Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 5 | 3.3 | 150.6 | (48.5-351.4) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 3 | 12.8 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 8 | 11.0 | 72.7 | (31.3-143.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

15

# Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 16.3 | 92.1 | (51.5-151.9) |  | Male | 6 | 11.1 | 53.9 | (19.7-117.4) |
| Female | 11 | 6.8 | 160.9 | (80.2-287.9) |  | Female | 4 | 9.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.4 | 145.2 | (46.8-339.0) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 0 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 17 | 9.8 | 172.9 | (100.6-276.8) |
| Female | 78 | 81.0 | 96.3 | (76.1-120.2) |  | Female | 11 | 9.6 | 114.9 | (57.3-205.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 8.7 | 114.3 | (54.7-210.3) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 18.0 | 88.9 | (50.8-144.4) |  |  |  |  |  |  |
| Female | 20 | 19.6 | 101.9 | (62.2-157.5) |  | Female | 6 | 6.9 | 87.3 | (31.9-190.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.4 | nc | (nc-nc) |  | Male | 7 | 6.3 | 111.4 | (44.6-229.5) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 4 | 7.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 70 | 53.8 | 130.0 | (101.4-164.3) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 10.5 | nc | (nc-nc) |  | Male | 5 | 4.0 | 125.5 | (40.5-293.0) |
| Female | 7 | 6.4 | 110.2 | (44.1-227.0) |  | Female | 1 | 2.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 7.0 | 129.0 | (58.9-245.0) |  | Male | 7 | 5.0 | 139.6 | (55.9-287.7) |
| Female | 5 | 5.4 | 91.9 | (29.6-214.5) |  | Female | 18 | 15.1 | 119.5 | (70.8-188.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 6.4 | 124.8 | (53.7-245.8) |  |  |  |  |  |  |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 18 | 18.6 | 96.6 | (57.2-152.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 29.1 | 99.7 | (66.8-143.3) |  | Male | 234 | 221.7 | 105.6 | (92.5-120.0) |
| Female | 43 | 36.6 | 117.5 | (85.1-158.3) |  | Female | 248 | 265.2 | 93.5 | (82.3-105.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

16

# Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 19.8 | 85.8 | (50.0-137.4) |  | Male | 11 | 12.7 | 86.7 | (43.2-155.1) |
| Female | 3 | 7.6 | nc | (nc-nc) |  | Female | 12 | 10.3 | 116.0 | (59.9-202.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 5.2 | nc | (nc-nc) |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 1 | 5.0 | nc | (nc-nc) |  | Female | 1 | 3.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 9 | 12.0 | 74.8 | (34.1-142.0) |
| Female | 78 | 79.7 | 97.8 | (77.3-122.1) |  | Female | 8 | 10.7 | 74.9 | (32.3-147.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 9.5 | 84.5 | (36.4-166.6) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 20.5 | 87.7 | (52.0-138.7) |  |  |  |  |  |  |
| Female | 23 | 21.1 | 108.8 | (69.0-163.3) |  | Female | 12 | 7.4 | 161.4 | (83.3-282.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 5.0 | nc | (nc-nc) |  | Male | 11 | 7.3 | 150.5 | (75.0-269.3) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 8 | 7.8 | 103.0 | (44.4-203.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  | Male | 43 | 60.1 | 71.5 | (51.8-96.4) |
| Female | 0 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 11.4 | nc | (nc-nc) |  | Male | 1 | 4.6 | nc | (nc-nc) |
| Female | 7 | 6.6 | 106.1 | (42.5-218.6) |  | Female | 0 | 3.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 0 | 3.6 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 9.8 | 71.1 | (28.5-146.5) |  | Male | 5 | 5.3 | 94.7 | (30.5-221.0) |
| Female | 2 | 6.8 | nc | (nc-nc) |  | Female | 4 | 15.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 7.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 17 | 18.5 | 91.8 | (53.4-146.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 35.0 | 40.0 | (21.8-67.1) |  | Male | 171 | 261.4 | 65.4 | (56.0-76.0) |
| Female | 19 | 38.8 | 49.0 | (29.5-76.5) |  | Female | 219 | 281.4 | 77.8 | (67.8-88.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

17

# Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 39.6 | 73.3 | (49.0-105.2) |  | Male | 27 | 25.4 | 106.2 | (70.0-154.5) |
| Female | 12 | 12.5 | 95.8 | (49.4-167.4) |  | Female | 25 | 18.8 | 132.9 | (86.0-196.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 7.4 | 107.4 | (46.3-211.7) |  | Male | 5 | 8.3 | 60.5 | (19.5-141.3) |
| Female | 5 | 6.1 | 81.4 | (26.2-189.9) |  | Female | 13 | 6.0 | 216.7 | (115.3-370.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 1.4 | nc | (nc-nc) |  | Male | 30 | 22.5 | 133.5 | (90.0-190.5) |
| Female | 170 | 156.3 | 108.7 | (93.0-126.4) |  | Female | 16 | 17.9 | 89.2 | (51.0-144.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 19.1 | 88.9 | (51.7-142.3) |
| Female | 3 | 5.3 | nc | (nc-nc) |  | Female | 3 | 8.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 42.0 | 66.6 | (44.2-96.3) |  |  |  |  |  |  |
| Female | 38 | 37.3 | 101.9 | (72.1-139.9) |  | Female | 11 | 13.1 | 84.2 | (42.0-150.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 10.1 | 79.3 | (34.1-156.2) |  | Male | 14 | 14.7 | 95.3 | (52.1-159.9) |
| Female | 7 | 2.5 | 280.6 | (112.4-578.2) |  | Female | 11 | 13.1 | 83.9 | (41.8-150.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 104 | 119.8 | 86.8 | (71.0-105.2) |
| Female | 1 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 23.2 | 94.7 | (59.3-143.4) |  | Male | 6 | 9.3 | 64.2 | (23.4-139.7) |
| Female | 11 | 12.0 | 91.5 | (45.6-163.7) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 5.9 | nc | (nc-nc) |  | Male | 8 | 4.6 | 173.1 | (74.5-341.1) |
| Female | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 15.8 | 114.0 | (67.5-180.1) |  | Male | 18 | 10.1 | 178.8 | (105.9-282.6) |
| Female | 11 | 10.5 | 104.6 | (52.1-187.2) |  | Female | 45 | 29.7 | 151.4 | (110.4-202.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 14.0 | 50.1 | (20.1-103.2) |  |  |  |  |  |  |
| Female | 2 | 4.3 | nc | (nc-nc) |  | Female | 22 | 34.7 | 63.4 | (39.7-96.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 38 | 69.7 | 54.5 | (38.6-74.8) |  | Male | 429 | 505.3 | 84.9 | (77.1-93.3) |
| Female | 41 | 67.0 | 61.2 | (43.9-83.1) |  | Female | 482 | 502.8 | 95.9 | (87.5-104.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

18

# Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 3 | 5.0 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 5 | 6.6 | 75.2 | (24.2-175.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

19

# Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 48 | 47.6 | 100.9 | (74.4-133.8) |  | Male | 24 | 30.3 | 79.2 | (50.7-117.8) |
| Female | 14 | 19.7 | 71.0 | (38.8-119.1) |  | Female | 29 | 26.8 | 108.1 | (72.4-155.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 8.9 | 135.3 | (69.8-236.3) |  | Male | 10 | 9.6 | 104.6 | (50.1-192.4) |
| Female | 11 | 8.5 | 129.8 | (64.7-232.2) |  | Female | 4 | 9.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 24 | 26.9 | 89.3 | (57.2-132.8) |
| Female | 206 | 207.3 | 99.4 | (86.3-113.9) |  | Female | 34 | 26.6 | 127.9 | (88.6-178.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 21.8 | 73.6 | (42.0-119.5) |
| Female | 5 | 6.9 | 72.5 | (23.4-169.2) |  | Female | 14 | 11.6 | 120.2 | (65.7-201.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 45 | 50.0 | 90.0 | (65.7-120.5) |  |  |  |  |  |  |
| Female | 56 | 57.0 | 98.3 | (74.2-127.6) |  | Female | 23 | 18.3 | 126.0 | (79.9-189.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 11.5 | 77.9 | (35.6-148.0) |  | Male | 18 | 17.4 | 103.6 | (61.4-163.8) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 18 | 20.8 | 86.3 | (51.1-136.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 3.4 | 145.1 | (46.8-338.6) |  | Male | 141 | 134.1 | 105.2 | (88.5-124.0) |
| Female | 5 | 3.3 | 153.8 | (49.6-358.9) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 26.7 | 101.3 | (66.7-147.4) |  | Male | 13 | 11.1 | 117.5 | (62.5-200.9) |
| Female | 14 | 16.9 | 82.9 | (45.3-139.1) |  | Female | 9 | 8.0 | 112.2 | (51.2-213.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 6.7 | 89.6 | (32.7-195.0) |  | Male | 9 | 7.0 | 128.6 | (58.7-244.2) |
| Female | 3 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 21 | 19.1 | 110.1 | (68.1-168.3) |  | Male | 15 | 12.3 | 122.2 | (68.3-201.5) |
| Female | 11 | 16.0 | 68.6 | (34.2-122.8) |  | Female | 44 | 38.4 | 114.5 | (83.2-153.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 16.1 | 93.2 | (52.1-153.7) |  |  |  |  |  |  |
| Female | 4 | 6.5 | nc | (nc-nc) |  | Female | 48 | 46.8 | 102.5 | (75.6-135.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 66 | 81.0 | 81.5 | (63.0-103.6) |  | Male | 573 | 591.6 | 96.9 | (89.1-105.1) |
| Female | 84 | 99.4 | 84.5 | (67.4-104.6) |  | Female | 693 | 713.9 | 97.1 | (90.0-104.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

20

# Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 5.3 | 112.9 | (41.2-245.8) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 18 | 29.2 | 61.7 | (36.6-97.6) |  | Female | 0 | 3.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 6.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 8 | 6.2 | 129.2 | (55.6-254.7) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 5 | 2.2 | 224.4 | (72.3-523.7) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 19 | 22.1 | 85.9 | (51.7-134.2) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.0 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 2.4 | 210.3 | (67.8-490.7) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 5 | 5.6 | 89.3 | (28.8-208.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 5 | 6.9 | 72.9 | (23.5-170.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 10.1 | 59.3 | (21.6-129.0) |  | Male | 79 | 81.5 | 97.0 | (76.8-120.8) |
| Female | 4 | 11.9 | nc | (nc-nc) |  | Female | 63 | 90.6 | 69.6 | (53.4-89.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

21

# Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 13 | 14.6 | 88.9 | (47.3-152.0) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 4.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 7 | 11.5 | 60.8 | (24.4-125.3) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  | Male | 3 | 0.9 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 4 | 2.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 6.3 | nc | (nc-nc) |  | Male | 44 | 48.1 | 91.4 | (66.4-122.7) |
| Female | 4 | 6.3 | nc | (nc-nc) |  | Female | 45 | 46.5 | 96.7 | (70.5-129.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

22

# Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 5 | 9.3 | 53.9 | (17.4-125.7) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 6.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 21 | 25.8 | 81.4 | (50.4-124.4) |
| Female | 1 | 4.3 | nc | (nc-nc) |  | Female | 18 | 30.1 | 59.7 | (35.4-94.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

23

# Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 15.4 | 110.3 | (64.2-176.6) |  | Male | 7 | 10.6 | 66.2 | (26.5-136.3) |
| Female | 4 | 5.9 | nc | (nc-nc) |  | Female | 5 | 9.2 | 54.1 | (17.4-126.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 8 | 9.4 | 85.4 | (36.8-168.2) |
| Female | 80 | 76.1 | 105.2 | (83.4-130.9) |  | Female | 8 | 8.6 | 93.2 | (40.1-183.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 8.4 | 71.7 | (26.2-156.1) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 5 | 3.9 | 126.8 | (40.9-295.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 17.3 | 69.5 | (35.9-121.5) |  |  |  |  |  |  |
| Female | 21 | 17.2 | 121.8 | (75.3-186.2) |  | Female | 8 | 6.4 | 125.5 | (54.0-247.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 4.2 | 168.3 | (67.4-346.8) |  | Male | 3 | 6.0 | nc | (nc-nc) |
| Female | 3 | 1.2 | nc | (nc-nc) |  | Female | 6 | 6.1 | 98.4 | (35.9-214.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 44 | 51.5 | 85.4 | (62.0-114.6) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 10.1 | nc | (nc-nc) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 1 | 5.8 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.7 | 74.9 | (24.2-174.9) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 6 | 5.1 | 118.3 | (43.2-257.6) |  | Female | 16 | 15.0 | 106.5 | (60.8-173.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 6.0 | 82.8 | (26.7-193.3) |  |  |  |  |  |  |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 15 | 17.6 | 85.5 | (47.8-141.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 27.8 | 68.2 | (41.1-106.6) |  | Male | 162 | 211.6 | 76.6 | (65.2-89.3) |
| Female | 36 | 32.0 | 112.6 | (78.9-156.0) |  | Female | 238 | 243.2 | 97.9 | (85.8-111.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

24

# Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 14.9 | 134.2 | (82.0-207.3) |  | Male | 7 | 9.5 | 73.3 | (29.4-151.1) |
| Female | 1 | 4.6 | nc | (nc-nc) |  | Female | 4 | 6.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 3 | 8.4 | nc | (nc-nc) |
| Female | 43 | 52.5 | 81.9 | (59.3-110.3) |  | Female | 6 | 6.4 | 93.7 | (34.2-203.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 7.2 | 83.2 | (30.4-181.2) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 15.2 | 118.5 | (70.2-187.3) |  |  |  |  |  |  |
| Female | 16 | 13.5 | 118.3 | (67.6-192.2) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 3.9 | 154.4 | (56.4-336.0) |  | Male | 5 | 5.6 | 89.6 | (28.9-209.1) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 6 | 4.9 | 123.4 | (45.1-268.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 30 | 47.4 | 63.2 | (42.7-90.3) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 8.7 | 149.8 | (79.7-256.2) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 4 | 4.2 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 5.9 | nc | (nc-nc) |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 6 | 3.8 | 158.1 | (57.7-344.1) |  | Female | 9 | 9.6 | 94.1 | (42.9-178.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 5.5 | 109.2 | (39.9-237.7) |  |  |  |  |  |  |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 19 | 11.9 | 159.1 | (95.7-248.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 26.9 | 122.6 | (84.4-172.2) |  | Male | 180 | 192.3 | 93.6 | (80.4-108.3) |
| Female | 32 | 23.9 | 134.1 | (91.7-189.4) |  | Female | 174 | 174.9 | 99.5 | (85.2-115.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

25

# Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 43 | 42.0 | 102.4 | (74.1-138.0) |  | Male | 29 | 28.3 | 102.6 | (68.7-147.3) |
| Female | 19 | 15.1 | 126.2 | (76.0-197.1) |  | Female | 23 | 22.8 | 101.0 | (64.0-151.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 8.8 | 113.9 | (54.5-209.4) |  | Male | 5 | 9.0 | 55.7 | (17.9-130.0) |
| Female | 4 | 7.4 | nc | (nc-nc) |  | Female | 7 | 7.2 | 97.4 | (39.0-200.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 15 | 25.0 | 59.9 | (33.5-98.8) |
| Female | 197 | 183.1 | 107.6 | (93.1-123.7) |  | Female | 19 | 21.5 | 88.4 | (53.2-138.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 22 | 21.6 | 101.8 | (63.8-154.2) |
| Female | 3 | 6.4 | nc | (nc-nc) |  | Female | 8 | 9.7 | 82.6 | (35.6-162.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 51 | 46.1 | 110.5 | (82.3-145.3) |  |  |  |  |  |  |
| Female | 42 | 44.2 | 95.1 | (68.5-128.5) |  | Female | 18 | 15.5 | 115.8 | (68.6-183.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 11.0 | 127.4 | (69.6-213.7) |  | Male | 23 | 15.9 | 144.6 | (91.6-216.9) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 18 | 15.7 | 114.9 | (68.0-181.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 8 | 3.5 | 226.6 | (97.6-446.5) |  | Male | 133 | 131.0 | 101.5 | (85.0-120.3) |
| Female | 2 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 21 | 26.3 | 79.9 | (49.5-122.2) |  | Male | 7 | 10.2 | 68.9 | (27.6-142.0) |
| Female | 9 | 14.3 | 63.0 | (28.7-119.5) |  | Female | 10 | 6.2 | 160.4 | (76.8-294.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 11 | 6.4 | 171.3 | (85.4-306.5) |  | Male | 11 | 7.0 | 156.6 | (78.1-280.3) |
| Female | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 17.8 | 89.9 | (51.3-145.9) |  | Male | 13 | 12.6 | 103.5 | (55.1-177.1) |
| Female | 10 | 12.7 | 78.7 | (37.7-144.8) |  | Female | 26 | 36.5 | 71.2 | (46.5-104.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 15.4 | 71.2 | (35.5-127.4) |  |  |  |  |  |  |
| Female | 9 | 5.1 | 174.9 | (79.8-332.0) |  | Female | 45 | 41.1 | 109.4 | (79.8-146.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 94 | 74.7 | 125.9 | (101.7-154.1) |  | Male | 577 | 557.8 | 103.4 | (95.2-112.2) |
| Female | 86 | 80.2 | 107.3 | (85.8-132.5) |  | Female | 623 | 598.8 | 104.0 | (96.0-112.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

26

# Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 20.3 | 133.1 | (87.7-193.6) |  | Male | 19 | 12.6 | 151.0 | (90.9-235.8) |
| Female | 11 | 8.3 | 133.2 | (66.4-238.4) |  | Female | 11 | 10.5 | 104.5 | (52.1-186.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.5 | 141.3 | (45.5-329.8) |  | Male | 4 | 4.1 | nc | (nc-nc) |
| Female | 6 | 3.4 | 177.8 | (64.9-387.0) |  | Female | 8 | 3.8 | 213.0 | (91.7-419.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 11 | 11.2 | 98.5 | (49.1-176.2) |
| Female | 86 | 84.3 | 102.0 | (81.6-125.9) |  | Female | 12 | 11.0 | 109.2 | (56.4-190.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 8.9 | 112.0 | (53.6-206.0) |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 1 | 4.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 20.9 | 90.9 | (54.7-142.0) |  |  |  |  |  |  |
| Female | 21 | 23.2 | 90.5 | (56.0-138.3) |  | Female | 7 | 7.3 | 95.7 | (38.4-197.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 4.9 | 102.2 | (32.9-238.5) |  | Male | 6 | 7.3 | 81.7 | (29.8-177.9) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 6 | 8.6 | 69.6 | (25.4-151.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 57 | 56.4 | 101.1 | (76.6-131.0) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 11.0 | 72.8 | (31.3-143.4) |  | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 5 | 6.9 | 72.7 | (23.4-169.7) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 2.9 | 280.5 | (120.8-552.8) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 7.8 | nc | (nc-nc) |  | Male | 5 | 4.7 | 106.5 | (34.3-248.4) |
| Female | 10 | 6.3 | 158.3 | (75.8-291.2) |  | Female | 9 | 14.2 | 63.4 | (28.9-120.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 6.7 | 104.8 | (42.0-216.0) |  |  |  |  |  |  |
| Female | 0 | 2.7 | nc | (nc-nc) |  | Female | 17 | 19.0 | 89.6 | (52.2-143.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 34.8 | 92.0 | (62.9-129.9) |  | Male | 253 | 247.0 | 102.4 | (90.2-115.8) |
| Female | 49 | 42.1 | 116.3 | (86.0-153.7) |  | Female | 290 | 290.0 | 100.0 | (88.8-112.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

27

# Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 5.9 | 135.5 | (58.3-266.9) |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 9 | 3.2 | 281.3 | (128.4-534.1) |
| Female | 24 | 22.1 | 108.6 | (69.6-161.6) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 6.0 | 116.1 | (46.5-239.2) |  |  |  |  |  |  |
| Female | 5 | 5.7 | 87.1 | (28.1-203.2) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 9 | 16.7 | 53.8 | (24.5-102.1) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 4 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 3 | 5.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 10.0 | 120.2 | (62.0-209.9) |  | Male | 71 | 71.7 | 99.0 | (77.3-124.8) |
| Female | 14 | 11.4 | 122.5 | (66.9-205.5) |  | Female | 69 | 75.7 | 91.2 | (71.0-115.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

28

# Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 7.1 | 127.4 | (58.1-241.9) |  | Male | 4 | 5.1 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 4.5 | nc | (nc-nc) |
| Female | 37 | 29.8 | 124.2 | (87.4-171.2) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 8.0 | 125.7 | (60.2-231.2) |  |  |  |  |  |  |
| Female | 14 | 7.4 | 189.7 | (103.6-318.2) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 2.0 | 301.0 | (109.9-655.1) |  | Male | 5 | 2.8 | 178.2 | (57.4-415.9) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 6 | 2.6 | 233.9 | (85.4-509.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 24 | 23.9 | 100.2 | (64.2-149.2) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.8 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.1 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 4 | 6.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 13 | 6.4 | 201.8 | (107.4-345.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 13.2 | 144.4 | (86.9-225.4) |  | Male | 104 | 99.6 | 104.4 | (85.3-126.5) |
| Female | 19 | 13.1 | 145.4 | (87.5-227.0) |  | Female | 125 | 98.5 | 126.9 | (105.6-151.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

29

# Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 90 | 73.2 | 122.9 | (98.8-151.0) |  | Male | 69 | 43.7 | 157.9 | (122.9-199.9) |
| Female | 28 | 24.0 | 116.6 | (77.5-168.5) |  | Female | 40 | 29.8 | 134.1 | (95.8-182.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 16 | 11.6 | 137.4 | (78.5-223.2) |  | Male | 10 | 14.3 | 69.9 | (33.5-128.5) |
| Female | 10 | 9.6 | 104.3 | (49.9-191.8) |  | Female | 14 | 10.9 | 128.5 | (70.2-215.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 5 | 2.4 | 206.9 | (66.7-482.7) |  | Male | 44 | 38.4 | 114.7 | (83.3-154.0) |
| Female | 310 | 246.8 | 125.6 | (112.0-140.4) |  | Female | 42 | 31.4 | 133.6 | (96.3-180.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 34 | 30.7 | 110.9 | (76.8-155.0) |
| Female | 6 | 7.1 | 84.9 | (31.0-184.8) |  | Female | 15 | 13.8 | 108.8 | (60.9-179.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 56 | 70.8 | 79.1 | (59.8-102.8) |  |  |  |  |  |  |
| Female | 60 | 64.6 | 92.9 | (70.9-119.6) |  | Female | 20 | 21.4 | 93.3 | (57.0-144.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 24 | 17.6 | 136.2 | (87.2-202.6) |  | Male | 29 | 26.1 | 111.1 | (74.4-159.5) |
| Female | 3 | 4.7 | nc | (nc-nc) |  | Female | 18 | 24.7 | 72.8 | (43.1-115.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 3.8 | nc | (nc-nc) |  | Male | 195 | 206.6 | 94.4 | (81.6-108.6) |
| Female | 0 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 32 | 37.5 | 85.3 | (58.3-120.4) |  | Male | 15 | 16.4 | 91.3 | (51.1-150.6) |
| Female | 15 | 20.4 | 73.6 | (41.1-121.3) |  | Female | 13 | 9.1 | 142.1 | (75.6-243.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 10.1 | 49.5 | (15.9-115.4) |  | Male | 4 | 5.9 | nc | (nc-nc) |
| Female | 0 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 33 | 27.1 | 121.8 | (83.8-171.0) |  | Male | 12 | 14.4 | 83.2 | (43.0-145.4) |
| Female | 29 | 18.0 | 161.5 | (108.1-231.9) |  | Female | 26 | 38.8 | 66.9 | (43.7-98.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 31 | 23.9 | 129.6 | (88.1-184.0) |  |  |  |  |  |  |
| Female | 7 | 7.9 | 89.0 | (35.7-183.5) |  | Female | 45 | 58.1 | 77.5 | (56.5-103.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 95 | 126.7 | 75.0 | (60.6-91.6) |  | Male | 884 | 871.9 | 101.4 | (94.8-108.3) |
| Female | 107 | 127.6 | 83.9 | (68.7-101.3) |  | Female | 872 | 842.9 | 103.4 | (96.7-110.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

30

# Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 5.7 | 87.3 | (28.1-203.7) |  | Male | 1 | 3.7 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 6 | 3.2 | 190.0 | (69.4-413.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 19 | 25.5 | 74.4 | (44.8-116.2) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 6.1 | 163.0 | (78.0-299.7) |  |  |  |  |  |  |
| Female | 1 | 6.7 | nc | (nc-nc) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 13 | 18.5 | 70.2 | (37.3-120.0) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 3.4 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 2.4 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 0 | 4.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 6 | 5.8 | 103.8 | (37.9-225.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 10.0 | 69.9 | (28.0-144.0) |  | Male | 55 | 75.4 | 72.9 | (54.9-94.9) |
| Female | 6 | 11.2 | 53.5 | (19.5-116.4) |  | Female | 60 | 84.9 | 70.7 | (53.9-91.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

31

# Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 3.1 | 162.7 | (52.4-379.7) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 8 | 10.2 | 78.5 | (33.8-154.7) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 5 | 9.5 | 52.5 | (16.9-122.5) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 5 | 2.4 | 206.9 | (66.7-482.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 5.6 | nc | (nc-nc) |  | Male | 33 | 38.3 | 86.0 | (59.2-120.9) |
| Female | 4 | 5.0 | nc | (nc-nc) |  | Female | 27 | 33.6 | 80.3 | (52.9-116.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

32

# Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 19.6 | 117.3 | (74.3-176.0) |  | Male | 14 | 12.0 | 116.3 | (63.5-195.1) |
| Female | 6 | 5.9 | 101.3 | (37.0-220.4) |  | Female | 11 | 8.1 | 136.5 | (68.1-244.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.3 | 153.0 | (49.3-357.1) |  | Male | 6 | 3.8 | 159.6 | (58.3-347.4) |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 15 | 10.5 | 143.3 | (80.1-236.3) |
| Female | 71 | 64.1 | 110.8 | (86.5-139.8) |  | Female | 7 | 8.0 | 87.6 | (35.1-180.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 8.1 | 86.2 | (34.5-177.6) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 19.9 | 80.5 | (46.0-130.7) |  |  |  |  |  |  |
| Female | 14 | 17.2 | 81.3 | (44.4-136.5) |  | Female | 5 | 5.5 | 90.4 | (29.1-211.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  | Male | 8 | 6.9 | 115.9 | (49.9-228.5) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 5 | 6.2 | 81.0 | (26.1-189.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 58 | 47.8 | 121.4 | (92.2-156.9) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 10.0 | 69.9 | (28.0-144.0) |  | Male | 6 | 4.4 | 135.8 | (49.6-295.5) |
| Female | 1 | 5.2 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 7.5 | 92.8 | (37.2-191.2) |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 5 | 4.8 | 104.8 | (33.8-244.6) |  | Female | 10 | 11.8 | 84.9 | (40.7-156.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 6.1 | 98.7 | (36.0-214.8) |  |  |  |  |  |  |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 6 | 13.8 | 43.4 | (15.9-94.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 33.1 | 72.6 | (46.5-108.0) |  | Male | 224 | 227.9 | 98.3 | (85.8-112.0) |
| Female | 27 | 30.4 | 88.9 | (58.6-129.3) |  | Female | 189 | 216.6 | 87.3 | (75.3-100.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

33

# Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 14.4 | 48.8 | (19.5-100.5) |  | Male | 6 | 9.9 | 60.5 | (22.1-131.6) |
| Female | 3 | 5.0 | nc | (nc-nc) |  | Female | 6 | 7.9 | 76.0 | (27.8-165.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 3.1 | 195.4 | (71.4-425.4) |  | Male | 5 | 3.2 | 157.1 | (50.6-366.5) |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 7 | 8.7 | 80.3 | (32.2-165.5) |
| Female | 70 | 65.4 | 107.0 | (83.4-135.2) |  | Female | 14 | 7.3 | 190.9 | (104.3-320.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 8.1 | 74.4 | (27.2-162.0) |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 5 | 3.3 | 149.4 | (48.1-348.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 16.1 | 93.3 | (52.2-153.9) |  |  |  |  |  |  |
| Female | 14 | 14.9 | 94.3 | (51.5-158.2) |  | Female | 4 | 5.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  | Male | 4 | 5.7 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 10 | 5.2 | 192.4 | (92.1-353.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 51 | 50.5 | 101.0 | (75.2-132.9) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 9.6 | 73.0 | (29.2-150.4) |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 3 | 5.0 | nc | (nc-nc) |  | Female | 4 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.1 | 81.4 | (26.2-190.0) |  | Male | 1 | 4.3 | nc | (nc-nc) |
| Female | 3 | 4.3 | nc | (nc-nc) |  | Female | 9 | 12.9 | 69.7 | (31.8-132.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 22 | 14.7 | 149.3 | (93.5-226.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 26.7 | 48.7 | (25.9-83.3) |  | Male | 155 | 200.4 | 77.3 | (65.6-90.5) |
| Female | 20 | 27.5 | 72.7 | (44.4-112.3) |  | Female | 207 | 208.2 | 99.4 | (86.3-113.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

34

# Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 14.4 | 97.5 | (53.3-163.6) |  | Male | 11 | 9.9 | 110.9 | (55.3-198.4) |
| Female | 3 | 5.0 | nc | (nc-nc) |  | Female | 9 | 7.9 | 114.0 | (52.0-216.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 8 | 3.2 | 251.3 | (108.2-495.2) |
| Female | 5 | 2.6 | 195.7 | (63.1-456.8) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 19 | 8.7 | 218.0 | (131.2-340.4) |
| Female | 74 | 65.4 | 113.1 | (88.8-142.0) |  | Female | 10 | 7.3 | 136.4 | (65.3-250.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 8.1 | 86.8 | (34.8-178.9) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 1 | 3.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 16.1 | 130.6 | (80.8-199.6) |  |  |  |  |  |  |
| Female | 17 | 14.9 | 114.5 | (66.6-183.3) |  | Female | 4 | 5.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.0 | nc | (nc-nc) |  | Male | 8 | 5.7 | 141.4 | (60.9-278.6) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 13 | 5.2 | 250.1 | (133.0-427.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 74 | 50.5 | 146.6 | (115.1-184.1) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 9.6 | 104.3 | (49.9-191.8) |  | Male | 5 | 3.6 | 140.4 | (45.2-327.6) |
| Female | 5 | 5.0 | 99.9 | (32.2-233.0) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.4 | nc | (nc-nc) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.1 | 81.4 | (26.2-190.0) |  | Male | 5 | 4.3 | 115.4 | (37.2-269.2) |
| Female | 7 | 4.3 | 164.5 | (65.9-338.9) |  | Female | 17 | 12.9 | 131.7 | (76.7-210.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 5.8 | 85.8 | (27.7-200.2) |  |  |  |  |  |  |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 16 | 14.7 | 108.6 | (62.0-176.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 30 | 26.7 | 112.4 | (75.8-160.5) |  | Male | 250 | 200.4 | 124.7 | (109.7-141.2) |
| Female | 27 | 27.5 | 98.1 | (64.6-142.8) |  | Female | 226 | 208.2 | 108.6 | (94.9-123.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

35

# Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 29.3 | 81.9 | (52.5-121.9) |  | Male | 18 | 18.3 | 98.4 | (58.3-155.5) |
| Female | 4 | 10.5 | nc | (nc-nc) |  | Female | 7 | 14.8 | 47.4 | (19.0-97.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.2 | 114.5 | (41.8-249.2) |  | Male | 3 | 5.9 | nc | (nc-nc) |
| Female | 2 | 4.8 | nc | (nc-nc) |  | Female | 4 | 4.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 5 | 1.0 | 498.5 | (160.7-1163.4) |  | Male | 17 | 16.2 | 104.9 | (61.1-168.0) |
| Female | 129 | 118.2 | 109.1 | (91.1-129.7) |  | Female | 9 | 14.5 | 62.3 | (28.4-118.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 13.0 | 38.4 | (12.4-89.6) |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 9 | 6.4 | 141.3 | (64.5-268.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 30.1 | 79.6 | (51.0-118.5) |  |  |  |  |  |  |
| Female | 25 | 30.5 | 81.9 | (53.0-121.0) |  | Female | 14 | 10.1 | 138.3 | (75.5-232.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 7.1 | nc | (nc-nc) |  | Male | 11 | 10.6 | 103.7 | (51.7-185.6) |
| Female | 5 | 2.0 | 244.0 | (78.6-569.4) |  | Female | 11 | 11.0 | 99.8 | (49.7-178.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 77 | 82.2 | 93.7 | (73.9-117.1) |
| Female | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 16.0 | 74.8 | (38.6-130.7) |  | Male | 5 | 6.8 | 74.1 | (23.9-172.8) |
| Female | 7 | 9.4 | 74.4 | (29.8-153.2) |  | Female | 6 | 4.3 | 140.4 | (51.3-305.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.1 | nc | (nc-nc) |  | Male | 7 | 3.7 | 188.1 | (75.4-387.6) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 11.5 | 43.6 | (14.0-101.7) |  | Male | 6 | 7.1 | 84.8 | (30.9-184.5) |
| Female | 5 | 8.6 | 58.1 | (18.7-135.6) |  | Female | 25 | 22.1 | 113.0 | (73.1-166.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 9.7 | 51.8 | (16.7-120.8) |  |  |  |  |  |  |
| Female | 1 | 3.5 | nc | (nc-nc) |  | Female | 24 | 26.2 | 91.7 | (58.7-136.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 39 | 50.1 | 77.9 | (55.4-106.5) |  | Male | 300 | 359.2 | 83.5 | (74.3-93.5) |
| Female | 41 | 54.9 | 74.6 | (53.6-101.3) |  | Female | 354 | 395.4 | 89.5 | (80.4-99.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

36

# Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 7.2 | nc | (nc-nc) |  | Male | 5 | 4.8 | 104.9 | (33.8-244.7) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 5 | 3.0 | 164.2 | (52.9-383.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 4.2 | nc | (nc-nc) |
| Female | 24 | 25.8 | 93.0 | (59.6-138.4) |  | Female | 6 | 2.6 | 227.6 | (83.1-495.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 7.6 | 131.9 | (63.2-242.7) |  |  |  |  |  |  |
| Female | 7 | 5.1 | 137.4 | (55.0-283.0) |  | Female | 0 | 2.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 15 | 23.5 | 63.8 | (35.7-105.2) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 4 | 5.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 8 | 5.7 | 140.4 | (60.5-276.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 13.3 | 97.5 | (51.9-166.7) |  | Male | 73 | 95.9 | 76.1 | (59.7-95.7) |
| Female | 4 | 9.4 | nc | (nc-nc) |  | Female | 77 | 77.9 | 98.9 | (78.0-123.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

37

# Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 4.8 | nc | (nc-nc) |  | Male | 6 | 2.9 | 210.1 | (76.7-457.3) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 16 | 15.0 | 107.0 | (61.1-173.8) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 4.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 3.5 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 11 | 13.1 | 84.1 | (41.9-150.5) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 3.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 8.1 | 99.0 | (42.6-195.0) |  | Male | 54 | 56.6 | 95.4 | (71.6-124.4) |
| Female | 5 | 6.8 | 73.0 | (23.5-170.4) |  | Female | 40 | 48.4 | 82.6 | (59.0-112.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

38

# Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 2.0 | 255.4 | (82.3-596.1) |
| Female | 14 | 12.3 | 113.7 | (62.1-190.8) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 3.7 | 134.8 | (43.5-314.7) |  |  |  |  |  |  |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 10 | 10.2 | 98.2 | (47.0-180.6) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 6.3 | 79.5 | (25.6-185.5) |  | Male | 35 | 43.8 | 79.8 | (55.6-111.0) |
| Female | 5 | 5.8 | 85.5 | (27.6-199.6) |  | Female | 42 | 40.5 | 103.8 | (74.8-140.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

39

# Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 49 | 42.2 | 116.1 | (85.9-153.5) |  | Male | 38 | 26.9 | 141.3 | (100.0-193.9) |
| Female | 19 | 16.7 | 114.1 | (68.6-178.1) |  | Female | 27 | 23.0 | 117.1 | (77.2-170.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 8.0 | 125.2 | (59.9-230.2) |  | Male | 10 | 8.6 | 116.7 | (55.8-214.5) |
| Female | 5 | 7.6 | 65.7 | (21.2-153.4) |  | Female | 6 | 7.7 | 77.5 | (28.3-168.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 1.5 | nc | (nc-nc) |  | Male | 26 | 23.8 | 109.2 | (71.3-160.0) |
| Female | 177 | 183.9 | 96.2 | (82.6-111.5) |  | Female | 19 | 22.7 | 83.6 | (50.3-130.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 26 | 19.9 | 130.5 | (85.2-191.2) |
| Female | 6 | 6.0 | 100.8 | (36.8-219.4) |  | Female | 12 | 10.2 | 117.7 | (60.8-205.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 37 | 43.8 | 84.5 | (59.5-116.5) |  |  |  |  |  |  |
| Female | 51 | 47.5 | 107.3 | (79.9-141.1) |  | Female | 12 | 15.9 | 75.3 | (38.9-131.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 10.6 | 94.0 | (45.0-172.8) |  | Male | 18 | 15.6 | 115.5 | (68.4-182.6) |
| Female | 4 | 3.3 | nc | (nc-nc) |  | Female | 19 | 17.6 | 108.0 | (65.0-168.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  | Male | 137 | 128.5 | 106.6 | (89.5-126.1) |
| Female | 2 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 29 | 24.2 | 119.9 | (80.3-172.3) |  | Male | 4 | 9.9 | nc | (nc-nc) |
| Female | 13 | 14.7 | 88.5 | (47.1-151.3) |  | Female | 3 | 6.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 6.2 | 97.5 | (35.6-212.2) |  | Male | 7 | 5.8 | 121.6 | (48.7-250.5) |
| Female | 2 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 24 | 17.0 | 140.8 | (90.2-209.5) |  | Male | 20 | 10.8 | 185.5 | (113.3-286.5) |
| Female | 21 | 13.4 | 156.2 | (96.7-238.9) |  | Female | 35 | 33.8 | 103.5 | (72.1-143.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 14.9 | 80.7 | (41.6-140.9) |  |  |  |  |  |  |
| Female | 6 | 5.5 | 108.4 | (39.6-236.0) |  | Female | 33 | 42.3 | 78.0 | (53.7-109.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 80 | 73.6 | 108.8 | (86.2-135.4) |  | Male | 604 | 537.3 | 112.4 | (103.6-121.8) |
| Female | 95 | 86.4 | 109.9 | (88.9-134.4) |  | Female | 633 | 620.7 | 102.0 | (94.2-110.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

40

# Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 52 | 42.3 | 122.8 | (91.7-161.1) |  | Male | 26 | 28.4 | 91.7 | (59.9-134.4) |
| Female | 18 | 15.4 | 117.1 | (69.4-185.1) |  | Female | 27 | 22.0 | 122.9 | (81.0-178.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 8.7 | 114.7 | (54.9-211.0) |  | Male | 8 | 9.1 | 88.2 | (38.0-173.8) |
| Female | 5 | 7.2 | 69.3 | (22.3-161.7) |  | Female | 9 | 7.2 | 125.5 | (57.3-238.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 29 | 25.1 | 115.6 | (77.4-166.0) |
| Female | 195 | 177.5 | 109.8 | (95.0-126.4) |  | Female | 22 | 21.3 | 103.2 | (64.6-156.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 19 | 22.0 | 86.4 | (52.0-134.9) |
| Female | 6 | 5.9 | 100.9 | (36.8-219.6) |  | Female | 8 | 9.5 | 84.0 | (36.2-165.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 37 | 46.6 | 79.4 | (55.9-109.4) |  |  |  |  |  |  |
| Female | 59 | 43.9 | 134.5 | (102.4-173.5) |  | Female | 11 | 15.1 | 72.8 | (36.3-130.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 11.2 | 125.0 | (68.3-209.7) |  | Male | 11 | 16.1 | 68.5 | (34.1-122.5) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 12 | 16.0 | 75.0 | (38.7-131.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 3.5 | 170.8 | (62.4-371.7) |  | Male | 129 | 135.9 | 94.9 | (79.2-112.8) |
| Female | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 33 | 26.5 | 124.5 | (85.7-174.9) |  | Male | 7 | 10.2 | 68.3 | (27.4-140.7) |
| Female | 7 | 14.1 | 49.7 | (19.9-102.5) |  | Female | 8 | 6.2 | 129.9 | (55.9-255.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 6.5 | nc | (nc-nc) |  | Male | 5 | 6.9 | 72.8 | (23.5-170.0) |
| Female | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 24 | 17.7 | 135.8 | (87.0-202.1) |  | Male | 16 | 12.4 | 129.0 | (73.7-209.6) |
| Female | 20 | 12.6 | 159.2 | (97.2-245.9) |  | Female | 40 | 33.7 | 118.7 | (84.8-161.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 15.9 | 75.6 | (39.0-132.0) |  |  |  |  |  |  |
| Female | 3 | 5.1 | nc | (nc-nc) |  | Female | 43 | 40.3 | 106.7 | (77.2-143.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 82 | 75.3 | 108.9 | (86.6-135.1) |  | Male | 567 | 565.4 | 100.3 | (92.2-108.9) |
| Female | 108 | 82.0 | 131.8 | (108.1-159.1) |  | Female | 644 | 588.8 | 109.4 | (101.1-118.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

41

# Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 8.0 | 137.8 | (68.7-246.6) |  | Male | 6 | 5.6 | 107.9 | (39.4-234.9) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 6 | 5.0 | 119.1 | (43.5-259.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.9 | nc | (nc-nc) |
| Female | 30 | 41.7 | 72.0 | (48.6-102.8) |  | Female | 3 | 4.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.6 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 5 | 2.1 | 232.7 | (75.0-543.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 9.1 | 99.1 | (45.2-188.1) |  |  |  |  |  |  |
| Female | 7 | 9.5 | 73.8 | (29.5-152.0) |  | Female | 6 | 3.5 | 173.0 | (63.2-376.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.2 | nc | (nc-nc) |  | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 31 | 27.9 | 110.9 | (75.4-157.5) |
| Female | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 5.3 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 7 | 2.7 | 262.8 | (105.3-541.6) |  | Female | 4 | 8.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 5 | 9.5 | 52.8 | (17.0-123.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 14.6 | 137.1 | (83.7-211.8) |  | Male | 122 | 112.0 | 109.0 | (90.5-130.1) |
| Female | 14 | 16.9 | 83.0 | (45.3-139.2) |  | Female | 124 | 131.9 | 94.0 | (78.2-112.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

42

# Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 3 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 7 | 5.7 | 123.8 | (49.6-255.2) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 5.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 17 | 20.6 | 82.5 | (48.1-132.2) |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 22 | 17.8 | 123.6 | (77.4-187.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

43

# Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 4.9 | nc | (nc-nc) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 7 | 3.0 | 235.8 | (94.5-485.9) |
| Female | 29 | 21.2 | 137.0 | (91.7-196.7) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 2.7 | 184.6 | (59.5-430.7) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 5.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 8 | 4.3 | 186.6 | (80.4-367.8) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 1.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 15 | 16.0 | 94.0 | (52.6-155.1) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 3.2 | 155.1 | (50.0-362.0) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 4.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 8.7 | nc | (nc-nc) |  | Male | 60 | 66.5 | 90.2 | (68.8-116.1) |
| Female | 3 | 7.9 | nc | (nc-nc) |  | Female | 64 | 64.3 | 99.6 | (76.7-127.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

44

# Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 359 | 478.0 | 75.1 | (67.5-83.3) |  | Male | 238 | 320.2 | 74.3 | (65.2-84.4) |
| Female | 146 | 184.8 | 79.0 | (66.7-92.9) |  | Female | 223 | 281.6 | 79.2 | (69.1-90.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 84 | 108.4 | 77.5 | (61.8-95.9) |  | Male | 113 | 99.9 | 113.1 | (93.2-135.9) |
| Female | 74 | 98.2 | 75.4 | (59.2-94.6) |  | Female | 128 | 86.3 | 148.3 | (123.7-176.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 20 | 17.0 | 117.5 | (71.7-181.5) |  | Male | 264 | 289.1 | 91.3 | (80.6-103.0) |
| Female | 1951 | 2117.3 | 92.1 | (88.1-96.3) |  | Female | 258 | 262.3 | 98.4 | (86.7-111.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 271 | 237.4 | 114.2 | (101.0-128.6) |
| Female | 95 | 75.4 | 126.0 | (101.9-154.0) |  | Female | 107 | 116.2 | 92.1 | (75.4-111.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 555 | 513.5 | 108.1 | (99.3-117.5) |  |  |  |  |  |  |
| Female | 545 | 534.1 | 102.0 | (93.7-111.0) |  | Female | 181 | 187.1 | 96.7 | (83.1-111.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 122 | 122.7 | 99.4 | (82.6-118.7) |  | Male | 174 | 178.5 | 97.5 | (83.5-113.1) |
| Female | 26 | 36.1 | 72.1 | (47.1-105.6) |  | Female | 187 | 191.6 | 97.6 | (84.1-112.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 49 | 54.9 | 89.2 | (66.0-118.0) |  | Male | 1737 | 1459.5 | 119.0 | (113.5-124.7) |
| Female | 39 | 52.1 | 74.9 | (53.3-102.4) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 255 | 288.7 | 88.3 | (77.8-99.8) |  | Male | 170 | 114.0 | 149.2 | (127.6-173.4) |
| Female | 167 | 170.1 | 98.2 | (83.9-114.3) |  | Female | 123 | 75.6 | 162.7 | (135.2-194.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 90 | 71.5 | 125.8 | (101.2-154.7) |  | Male | 95 | 110.4 | 86.0 | (69.6-105.1) |
| Female | 21 | 23.0 | 91.1 | (56.4-139.3) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 185 | 212.0 | 87.3 | (75.1-100.8) |  | Male | 140 | 146.8 | 95.4 | (80.2-112.6) |
| Female | 151 | 162.4 | 93.0 | (78.7-109.0) |  | Female | 436 | 462.7 | 94.2 | (85.6-103.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 254 | 173.3 | 146.5 | (129.1-165.7) |  |  |  |  |  |  |
| Female | 99 | 63.1 | 157.0 | (127.6-191.1) |  | Female | 447 | 478.2 | 93.5 | (85.0-102.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 872 | 839.4 | 103.9 | (97.1-111.0) |  | Male | 6566 | 6345.0 | 103.5 | (101.0-106.0) |
| Female | 880 | 968.2 | 90.9 | (85.0-97.1) |  | Female | 6881 | 7198.6 | 95.6 | (93.3-97.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

45

# Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 41 | 28.4 | 144.6 | (103.7-196.1) |  | Male | 32 | 17.2 | 185.8 | (127.1-262.3) |
| Female | 10 | 10.4 | 95.9 | (45.9-176.3) |  | Female | 16 | 13.0 | 123.3 | (70.4-200.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.7 | nc | (nc-nc) |  | Male | 8 | 5.6 | 142.4 | (61.3-280.7) |
| Female | 3 | 4.1 | nc | (nc-nc) |  | Female | 3 | 4.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 12 | 15.3 | 78.6 | (40.6-137.4) |
| Female | 87 | 105.8 | 82.3 | (65.9-101.5) |  | Female | 10 | 13.7 | 73.1 | (35.0-134.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 12.1 | 141.0 | (82.1-225.7) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 7 | 6.0 | 117.2 | (47.0-241.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 28.1 | 99.5 | (66.1-143.8) |  |  |  |  |  |  |
| Female | 29 | 28.9 | 100.2 | (67.1-144.0) |  | Female | 12 | 9.2 | 130.4 | (67.3-227.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 6.8 | 117.4 | (50.6-231.4) |  | Male | 8 | 10.2 | 78.5 | (33.8-154.7) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 12 | 11.0 | 109.5 | (56.5-191.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 82 | 78.9 | 103.9 | (82.7-129.0) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 14.8 | 87.6 | (46.6-149.8) |  | Male | 9 | 6.4 | 139.7 | (63.8-265.3) |
| Female | 10 | 8.7 | 115.4 | (55.2-212.2) |  | Female | 6 | 4.1 | 146.8 | (53.6-319.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 11 | 4.0 | 276.7 | (138.0-495.2) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 4 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 10.7 | 65.3 | (26.2-134.6) |  | Male | 5 | 6.0 | 83.6 | (26.9-195.1) |
| Female | 6 | 7.9 | 76.4 | (27.9-166.3) |  | Female | 23 | 16.9 | 136.1 | (86.2-204.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 9.3 | 85.8 | (36.9-169.0) |  |  |  |  |  |  |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 22 | 24.4 | 90.1 | (56.4-136.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 54 | 49.1 | 110.0 | (82.6-143.5) |  | Male | 378 | 340.7 | 111.0 | (100.0-122.7) |
| Female | 56 | 53.8 | 104.2 | (78.7-135.3) |  | Female | 345 | 363.8 | 94.8 | (85.1-105.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

46

# Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 4.9 | nc | (nc-nc) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 5 | 3.0 | 167.5 | (54.0-391.0) |
| Female | 22 | 21.2 | 103.6 | (64.9-156.9) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 5.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 4.3 | 117.1 | (37.7-273.2) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 1.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 16 | 17.5 | 91.7 | (52.4-148.9) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 4 | 1.2 | nc | (nc-nc) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 4.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 8.8 | 68.1 | (24.9-148.3) |  | Male | 60 | 68.6 | 87.5 | (66.8-112.7) |
| Female | 8 | 7.7 | 103.7 | (44.7-204.4) |  | Female | 64 | 63.8 | 100.3 | (77.2-128.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

47

# Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 9.8 | 82.0 | (35.3-161.5) |  | Male | 10 | 6.6 | 150.9 | (72.3-277.6) |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 11 | 4.7 | 233.9 | (116.6-418.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 4 | 5.8 | nc | (nc-nc) |
| Female | 34 | 39.7 | 85.7 | (59.3-119.7) |  | Female | 5 | 4.6 | 109.8 | (35.4-256.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 5.2 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 10.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 8 | 9.2 | 86.5 | (37.3-170.5) |  | Female | 1 | 3.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 36 | 32.4 | 111.0 | (77.8-153.7) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 6.3 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 3.9 | 127.1 | (41.0-296.7) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 10 | 7.3 | 137.3 | (65.7-252.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 7 | 9.2 | 76.0 | (30.4-156.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 17.9 | 44.8 | (19.3-88.2) |  | Male | 99 | 131.8 | 75.1 | (61.0-91.4) |
| Female | 13 | 17.7 | 73.2 | (39.0-125.3) |  | Female | 120 | 128.4 | 93.5 | (77.5-111.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

48

# Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 5.6 | nc | (nc-nc) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 6 | 2.6 | 231.9 | (84.7-504.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 26 | 20.7 | 125.8 | (82.1-184.3) |  | Female | 0 | 2.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 5.9 | 85.0 | (27.4-198.3) |  |  |  |  |  |  |
| Female | 8 | 5.4 | 149.1 | (64.2-293.7) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 16 | 16.4 | 97.3 | (55.6-158.0) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 3 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 3 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 9.6 | 52.1 | (16.8-121.6) |  | Male | 63 | 69.9 | 90.1 | (69.3-115.3) |
| Female | 6 | 9.2 | 65.6 | (23.9-142.7) |  | Female | 71 | 68.7 | 103.4 | (80.7-130.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

49

# Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 41 | 40.5 | 101.3 | (72.7-137.5) |  | Male | 26 | 25.6 | 101.5 | (66.3-148.8) |
| Female | 17 | 17.3 | 98.5 | (57.4-157.8) |  | Female | 23 | 22.5 | 102.4 | (64.9-153.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 7.5 | 66.5 | (21.4-155.2) |  | Male | 7 | 8.2 | 85.6 | (34.3-176.4) |
| Female | 7 | 7.2 | 96.8 | (38.8-199.5) |  | Female | 3 | 7.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 21 | 22.7 | 92.6 | (57.3-141.6) |
| Female | 194 | 175.3 | 110.6 | (95.6-127.4) |  | Female | 20 | 22.9 | 87.4 | (53.4-135.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 20 | 18.4 | 108.6 | (66.3-167.7) |
| Female | 6 | 5.7 | 105.7 | (38.6-230.0) |  | Female | 10 | 9.8 | 101.6 | (48.6-186.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 46 | 41.8 | 109.9 | (80.5-146.6) |  |  |  |  |  |  |
| Female | 64 | 49.2 | 130.1 | (100.2-166.2) |  | Female | 16 | 15.3 | 104.3 | (59.6-169.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 9.9 | 90.7 | (41.4-172.2) |  | Male | 14 | 14.7 | 95.2 | (52.0-159.7) |
| Female | 6 | 3.3 | 182.3 | (66.6-396.8) |  | Female | 19 | 18.2 | 104.6 | (62.9-163.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 2.9 | 207.7 | (75.8-452.0) |  | Male | 120 | 114.1 | 105.2 | (87.2-125.8) |
| Female | 4 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 25 | 22.5 | 111.3 | (72.0-164.3) |  | Male | 9 | 9.4 | 96.1 | (43.9-182.5) |
| Female | 12 | 14.4 | 83.6 | (43.2-146.1) |  | Female | 7 | 7.0 | 100.5 | (40.2-207.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.7 | nc | (nc-nc) |  | Male | 6 | 5.5 | 109.8 | (40.1-239.1) |
| Female | 4 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 16.2 | 49.5 | (21.3-97.4) |  | Male | 10 | 10.1 | 99.4 | (47.6-182.8) |
| Female | 17 | 13.7 | 124.1 | (72.3-198.8) |  | Female | 29 | 31.2 | 93.0 | (62.2-133.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 16 | 13.8 | 116.2 | (66.4-188.7) |  |  |  |  |  |  |
| Female | 4 | 5.5 | nc | (nc-nc) |  | Female | 48 | 38.7 | 123.9 | (91.4-164.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 66 | 69.5 | 95.0 | (73.5-120.9) |  | Male | 500 | 501.4 | 99.7 | (91.2-108.9) |
| Female | 88 | 86.9 | 101.3 | (81.3-124.8) |  | Female | 651 | 608.0 | 107.1 | (99.0-115.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

50

# Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 19.7 | 81.4 | (46.5-132.2) |  | Male | 18 | 11.6 | 155.0 | (91.8-244.9) |
| Female | 6 | 7.1 | 84.3 | (30.8-183.4) |  | Female | 8 | 8.1 | 98.4 | (42.4-193.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 12 | 10.1 | 119.2 | (61.5-208.2) |
| Female | 96 | 67.9 | 141.3 | (114.5-172.6) |  | Female | 17 | 9.0 | 189.0 | (110.1-302.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 8.1 | 61.7 | (19.9-144.0) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 5 | 3.9 | 127.0 | (40.9-296.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 18.7 | 53.6 | (25.7-98.6) |  |  |  |  |  |  |
| Female | 15 | 19.1 | 78.7 | (44.0-129.8) |  | Female | 7 | 5.9 | 117.9 | (47.2-242.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 4.8 | 104.6 | (33.7-244.1) |  | Male | 4 | 7.0 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 3 | 7.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 55 | 55.6 | 98.9 | (74.5-128.7) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 10.0 | nc | (nc-nc) |  | Male | 1 | 4.4 | nc | (nc-nc) |
| Female | 6 | 5.7 | 105.4 | (38.5-229.5) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 7.0 | 128.7 | (58.7-244.4) |  | Male | 2 | 3.6 | nc | (nc-nc) |
| Female | 7 | 5.1 | 136.5 | (54.7-281.3) |  | Female | 5 | 9.3 | 54.0 | (17.4-126.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 6.3 | 126.4 | (54.4-249.1) |  |  |  |  |  |  |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 16 | 16.2 | 98.6 | (56.3-160.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 31 | 35.0 | 88.6 | (60.2-125.7) |  | Male | 205 | 232.3 | 88.3 | (76.6-101.2) |
| Female | 26 | 36.9 | 70.4 | (46.0-103.2) |  | Female | 239 | 237.3 | 100.7 | (88.3-114.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

51

# Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 27.6 | 94.1 | (61.5-137.9) |  | Male | 16 | 17.9 | 89.3 | (51.0-145.1) |
| Female | 11 | 8.0 | 136.7 | (68.1-244.6) |  | Female | 21 | 11.8 | 178.2 | (110.2-272.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 5.5 | nc | (nc-nc) |  | Male | 3 | 5.7 | nc | (nc-nc) |
| Female | 6 | 4.1 | 145.5 | (53.1-316.7) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 10 | 16.1 | 61.9 | (29.6-113.9) |
| Female | 87 | 96.3 | 90.3 | (72.4-111.4) |  | Female | 11 | 11.4 | 96.2 | (48.0-172.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 13.5 | 96.1 | (51.1-164.4) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 35 | 29.6 | 118.4 | (82.5-164.7) |  |  |  |  |  |  |
| Female | 23 | 23.1 | 99.4 | (63.0-149.1) |  | Female | 9 | 8.2 | 109.5 | (49.9-207.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 7.0 | 85.5 | (31.2-186.1) |  | Male | 12 | 10.3 | 116.3 | (60.0-203.1) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 9 | 8.3 | 107.8 | (49.2-204.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 74 | 84.7 | 87.4 | (68.6-109.7) |
| Female | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 16.4 | 79.5 | (42.3-136.0) |  | Male | 5 | 6.5 | 76.6 | (24.7-178.7) |
| Female | 8 | 7.5 | 106.2 | (45.7-209.2) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.1 | nc | (nc-nc) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 11.6 | 69.2 | (29.8-136.3) |  | Male | 9 | 7.6 | 118.8 | (54.2-225.5) |
| Female | 4 | 6.7 | nc | (nc-nc) |  | Female | 28 | 18.3 | 153.1 | (101.7-221.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 9.9 | 141.1 | (77.1-236.8) |  |  |  |  |  |  |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 26 | 22.2 | 117.1 | (76.4-171.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 55 | 47.6 | 115.6 | (87.1-150.5) |  | Male | 333 | 357.7 | 93.1 | (83.4-103.6) |
| Female | 43 | 42.9 | 100.2 | (72.5-135.0) |  | Female | 319 | 316.1 | 100.9 | (90.1-112.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

52

# Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 4.0 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 15 | 18.2 | 82.6 | (46.2-136.2) |  | Female | 5 | 2.0 | 247.1 | (79.6-576.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 3.9 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 8 | 15.0 | 53.4 | (23.0-105.2) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 2.7 | 219.2 | (80.0-477.1) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 7.5 | 79.8 | (29.1-173.7) |  | Male | 51 | 57.1 | 89.3 | (66.5-117.4) |
| Female | 5 | 7.9 | 63.0 | (20.3-147.0) |  | Female | 41 | 57.5 | 71.3 | (51.1-96.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

53

# Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 85 | 86.8 | 98.0 | (78.3-121.2) |  | Male | 27 | 57.0 | 47.3 | (31.2-68.9) |
| Female | 32 | 33.0 | 96.8 | (66.2-136.7) |  | Female | 30 | 48.0 | 62.5 | (42.1-89.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 16 | 18.0 | 89.1 | (50.9-144.8) |  | Male | 14 | 18.2 | 77.0 | (42.1-129.2) |
| Female | 21 | 15.9 | 131.8 | (81.6-201.5) |  | Female | 17 | 15.4 | 110.5 | (64.4-177.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 45 | 50.9 | 88.4 | (64.5-118.3) |
| Female | 325 | 379.4 | 85.7 | (76.6-95.5) |  | Female | 40 | 45.9 | 87.1 | (62.2-118.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 41 | 43.2 | 94.9 | (68.1-128.7) |
| Female | 28 | 12.9 | 216.5 | (143.8-312.8) |  | Female | 25 | 20.4 | 122.4 | (79.2-180.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 111 | 93.4 | 118.8 | (97.7-143.1) |  |  |  |  |  |  |
| Female | 98 | 95.6 | 102.5 | (83.2-125.0) |  | Female | 40 | 32.8 | 122.1 | (87.2-166.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 25 | 22.3 | 112.1 | (72.5-165.5) |  | Male | 38 | 32.6 | 116.5 | (82.5-159.9) |
| Female | 8 | 6.5 | 123.9 | (53.3-244.1) |  | Female | 52 | 34.4 | 151.3 | (113.0-198.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 8 | 7.2 | 111.7 | (48.1-220.1) |  | Male | 265 | 265.8 | 99.7 | (88.1-112.5) |
| Female | 6 | 6.6 | 91.3 | (33.3-198.7) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 72 | 52.1 | 138.1 | (108.1-173.9) |  | Male | 26 | 20.7 | 125.8 | (82.2-184.4) |
| Female | 30 | 30.3 | 99.1 | (66.9-141.5) |  | Female | 13 | 13.4 | 96.8 | (51.5-165.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 17 | 13.0 | 131.1 | (76.3-209.9) |  | Male | 13 | 13.7 | 94.8 | (50.4-162.1) |
| Female | 6 | 4.2 | 144.2 | (52.7-314.0) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 26 | 36.9 | 70.5 | (46.1-103.4) |  | Male | 26 | 24.3 | 107.1 | (69.9-156.9) |
| Female | 18 | 27.8 | 64.7 | (38.3-102.3) |  | Female | 86 | 74.7 | 115.1 | (92.1-142.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 46 | 31.6 | 145.6 | (106.6-194.2) |  |  |  |  |  |  |
| Female | 15 | 11.1 | 135.6 | (75.8-223.6) |  | Female | 88 | 84.6 | 104.0 | (83.4-128.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 182 | 151.0 | 120.5 | (103.7-139.4) |  | Male | 1185 | 1132.3 | 104.7 | (98.8-110.8) |
| Female | 205 | 174.1 | 117.8 | (102.2-135.1) |  | Female | 1291 | 1267.6 | 101.8 | (96.4-107.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

54

# Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 3.8 | 132.8 | (42.8-309.9) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 12 | 16.0 | 74.9 | (38.7-130.9) |  | Female | 4 | 2.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 4.0 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 15 | 13.0 | 115.5 | (64.6-190.5) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 4 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 7.0 | 143.0 | (68.5-263.1) |  | Male | 51 | 51.0 | 100.1 | (74.5-131.6) |
| Female | 18 | 7.6 | 235.4 | (139.4-372.0) |  | Female | 63 | 53.6 | 117.6 | (90.4-150.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

55

# Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 47 | 55.9 | 84.1 | (61.8-111.8) |  | Male | 51 | 35.5 | 143.6 | (106.9-188.8) |
| Female | 16 | 22.4 | 71.3 | (40.7-115.8) |  | Female | 32 | 31.2 | 102.7 | (70.2-145.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 10.8 | 74.3 | (32.0-146.3) |  | Male | 9 | 11.4 | 79.0 | (36.1-150.0) |
| Female | 14 | 10.7 | 131.4 | (71.8-220.6) |  | Female | 7 | 10.3 | 67.9 | (27.2-139.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 35 | 31.5 | 111.0 | (77.3-154.3) |
| Female | 222 | 242.6 | 91.5 | (79.9-104.4) |  | Female | 36 | 30.5 | 118.1 | (82.7-163.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 29 | 25.9 | 112.0 | (75.0-160.9) |
| Female | 3 | 7.9 | nc | (nc-nc) |  | Female | 7 | 13.6 | 51.5 | (20.6-106.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 30 | 56.9 | 52.8 | (35.6-75.3) |  |  |  |  |  |  |
| Female | 41 | 62.4 | 65.7 | (47.2-89.2) |  | Female | 31 | 21.3 | 145.4 | (98.8-206.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 14.1 | nc | (nc-nc) |  | Male | 18 | 20.5 | 87.6 | (51.9-138.5) |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 26 | 23.5 | 110.6 | (72.2-162.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 4.6 | 129.6 | (47.3-282.0) |  | Male | 155 | 169.7 | 91.3 | (77.5-106.9) |
| Female | 7 | 5.0 | 139.0 | (55.7-286.5) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 31 | 31.7 | 97.7 | (66.4-138.7) |  | Male | 10 | 13.0 | 76.9 | (36.8-141.5) |
| Female | 16 | 19.8 | 81.0 | (46.2-131.5) |  | Female | 6 | 8.9 | 67.7 | (24.7-147.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 8.2 | nc | (nc-nc) |  | Male | 12 | 8.7 | 137.2 | (70.8-239.7) |
| Female | 2 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 33 | 22.6 | 145.8 | (100.4-204.8) |  | Male | 16 | 14.3 | 112.1 | (64.0-182.0) |
| Female | 22 | 18.6 | 118.6 | (74.3-179.5) |  | Female | 46 | 46.9 | 98.2 | (71.9-131.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 19.2 | 62.4 | (32.2-108.9) |  |  |  |  |  |  |
| Female | 3 | 7.4 | nc | (nc-nc) |  | Female | 46 | 56.4 | 81.5 | (59.7-108.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 47 | 98.6 | 47.7 | (35.0-63.4) |  | Male | 607 | 711.1 | 85.4 | (78.7-92.4) |
| Female | 74 | 118.3 | 62.5 | (49.1-78.5) |  | Female | 740 | 832.1 | 88.9 | (82.6-95.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

56

# Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 4 | 10.5 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 7 | 7.6 | 91.6 | (36.7-188.8) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 2.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 4.4 | nc | (nc-nc) |  | Male | 24 | 31.1 | 77.3 | (49.5-115.0) |
| Female | 7 | 5.1 | 137.8 | (55.2-284.0) |  | Female | 24 | 34.8 | 69.0 | (44.2-102.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

57

# Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 33.5 | 80.7 | (53.2-117.4) |  | Male | 19 | 20.4 | 93.3 | (56.1-145.6) |
| Female | 8 | 11.3 | 70.8 | (30.5-139.6) |  | Female | 11 | 15.0 | 73.2 | (36.5-131.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 5.7 | 88.5 | (28.5-206.4) |  | Male | 6 | 6.5 | 92.5 | (33.8-201.2) |
| Female | 5 | 4.9 | 102.4 | (33.0-238.9) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 24 | 17.9 | 134.0 | (85.8-199.3) |
| Female | 131 | 123.6 | 105.9 | (88.6-125.7) |  | Female | 13 | 15.1 | 85.9 | (45.7-146.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 13.6 | 73.4 | (35.1-135.0) |
| Female | 2 | 3.9 | nc | (nc-nc) |  | Female | 5 | 6.7 | 74.8 | (24.1-174.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 33.1 | 81.7 | (53.8-118.8) |  |  |  |  |  |  |
| Female | 30 | 31.4 | 95.6 | (64.5-136.5) |  | Female | 9 | 10.5 | 85.6 | (39.1-162.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 7.7 | nc | (nc-nc) |  | Male | 19 | 11.7 | 161.8 | (97.3-252.6) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 7 | 11.7 | 60.0 | (24.0-123.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 75 | 83.9 | 89.4 | (70.3-112.0) |
| Female | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 16.9 | 94.6 | (54.1-153.7) |  | Male | 6 | 7.5 | 79.9 | (29.2-174.0) |
| Female | 5 | 10.0 | 49.9 | (16.1-116.6) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.4 | nc | (nc-nc) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 12.8 | 125.1 | (71.5-203.2) |  | Male | 8 | 7.3 | 110.3 | (47.5-217.4) |
| Female | 5 | 8.8 | 56.7 | (18.3-132.4) |  | Female | 31 | 22.0 | 141.0 | (95.8-200.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 10.5 | 76.4 | (32.9-150.6) |  |  |  |  |  |  |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 34 | 27.6 | 123.1 | (85.2-172.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 39 | 56.9 | 68.6 | (48.8-93.8) |  | Male | 352 | 390.9 | 90.0 | (80.9-100.0) |
| Female | 60 | 61.1 | 98.3 | (75.0-126.5) |  | Female | 395 | 415.1 | 95.2 | (86.0-105.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

58

# Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 52 | 77.2 | 67.4 | (50.3-88.4) |  | Male | 52 | 50.3 | 103.4 | (77.2-135.6) |
| Female | 16 | 29.9 | 53.6 | (30.6-87.0) |  | Female | 52 | 44.6 | 116.6 | (87.1-153.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 20 | 17.5 | 114.5 | (69.9-176.8) |  | Male | 15 | 15.7 | 95.6 | (53.4-157.6) |
| Female | 15 | 15.9 | 94.1 | (52.6-155.2) |  | Female | 9 | 13.8 | 65.1 | (29.7-123.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 47 | 45.8 | 102.6 | (75.4-136.4) |
| Female | 326 | 328.6 | 99.2 | (88.7-110.6) |  | Female | 49 | 41.9 | 116.9 | (86.5-154.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 40 | 35.7 | 112.1 | (80.1-152.6) |
| Female | 6 | 11.5 | 52.3 | (19.1-113.9) |  | Female | 18 | 18.5 | 97.3 | (57.7-153.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 70 | 79.1 | 88.5 | (69.0-111.9) |  |  |  |  |  |  |
| Female | 64 | 83.7 | 76.5 | (58.9-97.6) |  | Female | 31 | 29.5 | 105.2 | (71.4-149.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 16 | 19.3 | 83.0 | (47.4-134.8) |  | Male | 28 | 28.1 | 99.7 | (66.2-144.1) |
| Female | 10 | 5.9 | 170.6 | (81.7-313.8) |  | Female | 26 | 30.9 | 84.2 | (55.0-123.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 11 | 9.8 | 112.7 | (56.2-201.6) |  | Male | 255 | 227.4 | 112.1 | (98.8-126.8) |
| Female | 4 | 9.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 33 | 43.8 | 75.3 | (51.8-105.7) |  | Male | 12 | 17.9 | 66.9 | (34.5-116.9) |
| Female | 17 | 26.9 | 63.2 | (36.8-101.2) |  | Female | 10 | 12.0 | 83.5 | (40.0-153.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 11.1 | 44.9 | (14.5-104.7) |  | Male | 24 | 19.5 | 122.9 | (78.7-182.9) |
| Female | 0 | 3.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 32 | 34.0 | 94.1 | (64.4-132.9) |  | Male | 25 | 22.5 | 111.0 | (71.8-163.9) |
| Female | 16 | 26.0 | 61.5 | (35.1-99.8) |  | Female | 84 | 72.4 | 116.0 | (92.5-143.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 19 | 26.6 | 71.3 | (42.9-111.4) |  |  |  |  |  |  |
| Female | 10 | 10.1 | 98.9 | (47.4-182.0) |  | Female | 67 | 76.0 | 88.1 | (68.3-111.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 99 | 134.8 | 73.4 | (59.7-89.4) |  | Male | 928 | 1000.3 | 92.8 | (86.9-98.9) |
| Female | 112 | 157.4 | 71.2 | (58.6-85.6) |  | Female | 1020 | 1139.5 | 89.5 | (84.1-95.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

59

# Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 27.1 | 70.2 | (42.2-109.6) |  | Male | 21 | 16.9 | 124.1 | (76.8-189.7) |
| Female | 5 | 9.5 | 52.5 | (16.9-122.6) |  | Female | 15 | 13.1 | 114.5 | (64.1-188.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 4.8 | 145.4 | (58.2-299.5) |  | Male | 13 | 5.4 | 240.2 | (127.8-410.8) |
| Female | 6 | 4.2 | 142.4 | (52.0-309.9) |  | Female | 5 | 4.4 | 114.4 | (36.9-266.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 13 | 15.0 | 86.8 | (46.2-148.4) |
| Female | 113 | 104.6 | 108.0 | (89.0-129.9) |  | Female | 15 | 12.9 | 116.2 | (65.0-191.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 12.0 | 92.0 | (45.9-164.6) |
| Female | 5 | 3.5 | 143.2 | (46.2-334.2) |  | Female | 5 | 5.7 | 88.0 | (28.4-205.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 34 | 27.4 | 123.9 | (85.8-173.2) |  |  |  |  |  |  |
| Female | 30 | 27.3 | 109.8 | (74.1-156.8) |  | Female | 9 | 9.0 | 100.2 | (45.7-190.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 6.5 | 91.6 | (33.5-199.4) |  | Male | 11 | 9.8 | 112.0 | (55.9-200.5) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 8 | 10.0 | 80.2 | (34.5-158.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 87 | 76.0 | 114.5 | (91.7-141.3) |
| Female | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 14.8 | 60.9 | (27.8-115.7) |  | Male | 8 | 6.2 | 128.7 | (55.4-253.6) |
| Female | 7 | 8.4 | 83.6 | (33.5-172.2) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.8 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 3 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 10.6 | 151.1 | (86.3-245.3) |  | Male | 11 | 6.4 | 170.8 | (85.1-305.6) |
| Female | 6 | 7.7 | 78.0 | (28.5-169.7) |  | Female | 31 | 19.4 | 159.5 | (108.4-226.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 9.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 3.1 | nc | (nc-nc) |  | Female | 25 | 23.2 | 107.9 | (69.8-159.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 46 | 46.9 | 98.2 | (71.9-131.0) |  | Male | 360 | 331.6 | 108.6 | (97.6-120.4) |
| Female | 55 | 49.4 | 111.4 | (83.9-145.0) |  | Female | 380 | 352.3 | 107.9 | (97.3-119.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

60